Scripps Research Institute Scientists Shed Light on Cause of Spastic Paraplegia
Posted: September 30, 2014 at 8:45 am
Contact Information
Available for logged-in reporters only
LA JOLLA, CASeptember 29, 2014Scientists at The Scripps Research Institute (TSRI) have discovered that a gene mutation linked to hereditary spastic paraplegia, a disabling neurological disorder, interferes with the normal breakdown of triglyceride fat molecules in the brain. The TSRI researchers found large droplets of triglycerides within the neurons of mice modeling the disease.
The findings, reported this week online ahead of print by the journal Proceedings of the National Academy of Sciences, point the way to potential therapies and showcase an investigative strategy that should be useful in determining the biochemical causes of other genetic illnesses. Scientists in recent decades have linked thousands of gene mutations to human diseases, yet many of the genes in question code for proteins of unknown function.
We often need to understand the protein function that is disrupted by a gene mutation, if were going to understand the mechanistic basis for the disease and move towards developing a therapy, and that is what weve tried to do here, said Benjamin F. Cravatt, professor and chair of TSRIs Department of Chemical Physiology.
There is currently no treatment for hereditary spastic paraplegia (HSP), a set of genetic illnesses whose symptoms include muscle weakness and stiffness, and in some cases cognitive impairments. About 100,000 people worldwide live with HSP.
Uncovering Clues
In the new study, Cravatt and members of his laboratory, including graduate student Jordon Inloes and postdoctoral fellow Ku-Lung Hsu, focused on DDHD2, an enzyme of unclear function whose gene is mutated in a subset of HSP cases. These cases involving DDHD2 disruption feature cognitive defects as well as spasticity and muscle wasting, so theyre among the more devastating forms of this illness, said Cravatt.
To start, the researchers created a mouse model of DDHD2-related HSP, in which a targeted deletion from the DDHD2 gene eliminated the expression of the DDHD2 protein. These mice showed symptoms similar to those of HSP patients, including abnormal gait and lower performance on tests of movement and cognition, said Inloes.
Prior research had suggested that the DDHD2 enzyme is expressed in the brain and is involved somehow in lipid metabolism. One study reported elevated levels of an unknown fat molecule in the brains of DDHD2-mutant HSP patients. Cravatts team compared the tissues of the no-DDHD2 mice to the tissues of mice with normal versions of the gene, and also found that the mutant mice had much higher levels of a type of fat molecule, principally in the brain.
Read more from the original source:
Scripps Research Institute Scientists Shed Light on Cause of Spastic Paraplegia